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Telomeres are specialized structures of repetitive nucleotide
sequences that cap the ends of human chromosomes. Their main
purpose is to maintain genome stability and integrity, and to
protect the cell from progressive DNA shortening during repeated
division. Human enzyme telomerase complex maintains the
length of telomere repeats.1 Despite the high levels of telomerase
activity in cancer cells, telomere shortening can still occur. Some
recent reports describe reduced telomere length in myeloﬁbrosis
(MF) regardless of hydroxycarbamide therapy, suggesting a
possible prognostic relevance for this biomarker.2–4 As yet, no
studies have investigated telomere dynamics following treatment
with ruxolitinib, a JAK1/2 inhibitor approved for the treatment of
intermediate-2 and high risk MF, primary or post-polycythemia
vera (PV) and essential thrombocytemia (ET).5
Eight primary MF and three post ET MF patients were given
15 mg or 20 mg of oral ruxolitinib twice daily (BID) depending on
baseline platelet counts (100 000/μl to 200 000/μl or4200 000/μl,
respectively). The drug dose was escalated to 25 mg BID in
patients with an inadequate response and reduced when platelet
counts dropped to o100 000/μl. Treatment was stopped when
platelet levels fell below 50 000/μl. Telomere lengths were
analyzed on unfractionated peripheral blood samples by quanti-
tative PCR (q-PCR) as described by Cawthon6 and assessed before
and after ruxolitinib at a median of 1000 days (range 113–1152).
Primers tel1b(For) 5′-CGG TTT GTT TGG GTT TGG GTT TGG GTT
TGG GTT TGG GTT-3′ (270 nM) and tel2b(Rev) 5′-GGC TTG CCT TAC
CCT TAC CCT TAC CCT TAC CCT TAC CCT-3′(900 nM) and primers
36B4 36B4u (For) 5′-CAG CAA GTG GGA AGG TGT AAT CC-3′
(300 nM) and 36B4d (Rev) 5′-CCC ATT CTA TCA TCA ACG GGT
ACA A-3′ (500 nM) were used for telomere mixture ampliﬁca-
tion and gene ampliﬁcation, respectively. The relative telomere
length (RTL) was determined as the telomere (T) to single copy
gene (36B4) (S) ratio (T/S) normalized to a reference sample
(K-562 DNA). Peripheral blood samples were also collected from
11 age-and sex-matched controls from a larger database of 100
healthy subjects.
Median age at diagnosis was 72 years (range 53–83). The JAK2
V617F mutation was detected in seven patients, while CALR and
MPL were found in two and one patient, respectively. One patient
was triple negative. All patients had splenomegaly with a median
enlargement of 17 cm below the costal margin. Based on the IPSS
scores, six patients were assigned to the intermediate-2 risk
category and ﬁve to the high risk category. Ruxolitinib was
administered for a median of 1000 days (range 113–1152). Overall,
patients received a median of 22 g of ruxolitinib (range 4.6–44.5).
All patients showed improvement in constitutional symptoms and
quality of life, median weight gain was 7 kg (range 4–14 kg).
Splenomegaly decreased by 60% (range 20–100%). Related
samples Wilcoxon signed-rank test performed before treatment
with ruxolitinib showed that the mean RTL was shorter in patients
compared with age-and sex-matched healthy controls (1.08 vs
1.26, respectively; P= 0.09). After treatment, median RTL increased
signiﬁcantly (1.30 vs 1.08; P= 0.018), showing overlapping values
with the healthy controls (Figure 1). Median RTL elongation from
baseline was 15%. Univariate and multivariate analyses included
the following parameters: primary MF, presence of the JAK2 V617F
mutation, high IPSS score, a decrease in splenomegaly of 450%,
450% bone marrow (BM) cellularity before and after treatment,
duration of treatment41000 days and total drug dose of422 g.
Variables with a P-value lower than 0.2 in univariate analysis were
included in multivariate analysis using a multi-step forward binary
logistic regression model, where RLT 415% from baseline was
considered a dependent variable. Only pretreatment BM cellularity
of450% signiﬁcantly correlated with415% telomere elongation
(P= 0.004).
In our small cohort of patients, telomere length was restored to
normal values after treatment with ruxolitinib. Our observation
could stem from a non-speciﬁc anti-cytokine action or qualitative
changes in clonal hematopoiesis. Indeed, it is possible that
ruxolitinib mediates modulation of the BM microenvironment,
thereby stimulating stem cell hematopoiesis.7 Moreover, It has
been demonstrated that oxidative stress and inﬂammation
contributes to a signiﬁcant decrease in telomerase activity causing
telomere shortening.8 Ruxolitinib suppresses proinﬂammatory
cytokines through interference with JAK-signal transducer and
activator of transcription (STAT) signaling, and thus reverses a
potential mechanism of telomere shortening. Despite the
uniqueness of this study some limitations need to be noted. First
of all, the cohort of patients was relatively small and we did not
determine sorted myeloid compartment telomere length. Our
preliminary observations need to be validated in the context of
controlled studies to achieve new insights on the role of treatment
with telomerase inhibitors in MF patients.9
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Figure 1. Relative telomere lengths (RTL) before and after ruxolitinib
treatment in 11 patients and a group of age- and sex-matched
healthy controls. Ruxo= ruxolitinib; NS=not signiﬁcant.
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